<DOC>
	<DOC>NCT00036556</DOC>
	<brief_summary>This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.</brief_summary>
	<brief_title>Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>Have been diagnosed with prostate cancer. Have a rising PSA while on hormone therapy or following surgical castration. Have evidence of distant metastatic disease on screening bone scan or CT scan. Have received cytotoxic chemotherapy. Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Hormone-Refractory Prostate Cancer</keyword>
</DOC>